GATA announced HUGE earnings yesterday - now let the action begin
Published: Tue, 11/27/18
 Traders and Investors, You've got to see this... A tiny company, Groupe Athena, Inc (GATA), with a insanely small market cap of around $2.5m, just announced this bombshell earnings news after the market close yesterday, check it out... Groupe Athena, Inc. Posts 1st Quarter Results Mumbai, India, Nov. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Groupe Athena, Inc. (GATA) announced today revenues of $10,211,529 for the period ending September 30, 2018. Operating income before Depreciation and Amortization was $1,480,511 and reflects a Research and Development charge of $92,659. Net income for the period was $1,167,101 or $.02 per share. The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth. Source: https://finance.yahoo.com/news/groupe-athena-inc-posts-1st-213000111.htmlThese are seriously amazing earnings results from a Company trading at $0.05 with a market cap of just $2.5m. In fact, I might go out on a limb here and say GATA, a Company with such massive earnings and such a low valuation, is practically unheard of. About GATA... Serving India and South East Asia, Groupe Athena has been serving companies abroad in obtaining FDA approval for pharmaceuticals, medical products and devices for export to the USA. Their goal is to ensure each of our clients passes FDA inspection by assisting them from concept through development, with consultation through all the regulatory requirements, filings, and processes to achieve FDA compliance and approval. With offices in India and America, the expert consultants of Groupe Athena are in position to go to American target companies and the regulatory authorities directly, consulting with our clients in the East to serve them completely in providing consultancy services for FDA compliance. Services include providing technical and regulatory consulting for biotechnical products, pharmaceuticals [over the counter, prescription and generics], diagnostics, medical equipment, and devices. The FDA inspection process is traditionally complicated, especially for foreign drug and medical companies trying to export to the USA. With broad spectrum consultancy and assistance through this process, our client base can count on reduced risk, follow-through on steps necessary for FDA compliance and identifying and solving breaches in compliance. From concept through final approval, Groupe Athena navigates companies through every requirement of the process including pharmaceutical consulting, development, and regulatory compliance to achieve FDA approval and export pharmaceuticals and medical products and equipment to the USA. The last time it announced earnings news like this, back in July, GATA ran from around $0.065 all the way to $0.12 in two days. So there it is, do your own research but I'd strongly suggest to keep an eye on GATA tomorrow. All the best. SmallCapMomo.com --------------------------------------------------------------------------------------------------------
Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity. Disclaimer Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here. SmallCapMomo.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SmallCapMomo.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. SmallCapMomo.com does not offer such advice or analysis, and SmallCapMomo.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, SmallCapMomo.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SmallCapMomo.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SmallCapMomo.com is not responsible for any claims made by the companies advertised herein. SmallCapMomo.com may receive compensation and they, its employees and/or affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in SmallCapMomo.com statements and opinions and such statements and opinions cannot be considered independent. SmallCapMomo.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, SmallCapMomo.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. SmallCapMomo.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to close positions they have entered into at any given time including before or after the release of the companies profile. SmallCapMomo.com has been compensated two thousand dollars via electronic transfer from a non-affiliated third party for the profile of GATA. SmallCapMomo.com does not accept compensation in restricted or free-trading shares for its marketing services of the company being profiled. However the third party that has compensated SmallCapMomo.com may hold free-trading shares of the company being profiled and could very well be selling shares of the company’s stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If SmallCapMomo.com ever does accept compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the position of those free trading shares received as compensation for our services at the time our promotional material is released to the public, as well as information on our intention to sell these shares during the promotional period or thereafter. |